Sort Through Meds for Managing Hemophilia

New meds Jivi (JIH-vee) and Rebinyn (reh-bee-NYNE) will raise questions about managing bleeding in hemophilia patients.

Jivi (recombinant PEGylated factor VIII) will be for hemophilia A. It will compete with other long-acting (Adynovate, Eloctate, etc) and short-acting (Kogenate FS, Recombinate, etc) factor VIII products.

Rebinyn (recombinant glycoPEGylated factor IX) is for the less common hemophilia B. It's an alternative to long-acting (Alprolix, Idelvion, etc) or short-acting (BeneFix, Ixinity, etc) factor IX products.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote